67 episodes

Highlights and interviews from the 2016 ESMO congress in Copenhagen, Denmark.

ESMO 2016 ecancer

    • Medicine

Highlights and interviews from the 2016 ESMO congress in Copenhagen, Denmark.

    • video
    Comment: Ribociclib for breast cancer

    Comment: Ribociclib for breast cancer

    Dr De Azambuja meets with ecancertv at ESMO 2016 to review abstracts presented at the conference, beginning with that of Dr Hortobagyi on ribociclib for breast cancer.

    • 1 min
    • video
    A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

    A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

    Dr Stahler speaks with ecancer at ESMO 2016 about his research targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) 3 cell lines, with expression levels have a potentially predictive value for patient response.

    He summarises the results in cell lines and how this has translated to predicted and actual patient response.

    Dr Stahler notes that this was an exploratory trial, and considers avenues of further upcoming validation trials.

    • 2 min
    • video
    Firstline pembrolizumab for metastatic urothelial cancer

    Firstline pembrolizumab for metastatic urothelial cancer

    Dr Balar speaks with ecancertv at ESMO 2016 about the outcomes of patients receiving immune checkpoint therapy as a first line treatment against metastatic urothelial cancer.

    • 2 min
    • video
    KRAS in the clinic and conference

    KRAS in the clinic and conference

    Dr Vivancos meets with ecancertv at ESMO 2016 to discuss how her lab is targeting KRAS mutations, with liquid biopsies guiding research.

    She discusses clinical practice, working with lung adenocarcinomas, metastatic colorectal cancer and pancreatic cancer, and the opportunities of collaboration and professional development through the conference.

    Considering the news from ESMO so far, Dr Vivancos anticipates novel biomarkers and immunotherapy having a significant influence over future standards of care.

    • 3 min
    • video
    Comment: Ipilimumab in high risk stage III melanoma

    Comment: Ipilimumab in high risk stage III melanoma

    Dr De Azambuja talks to ecancertv at ESMO 2016 about the finding that ipilimumab as adjuvant therapy improved overall survival in high risk stage III melanoma.

    • 1 min
    • video
    Ipilimumab as adjuvant therapy improves OS in high risk melanoma

    Ipilimumab as adjuvant therapy improves OS in high risk melanoma

    Prof Eggermont speaks with ecancertv at ESMO 2016 about results from the EORTC 18071 phase III trial of ipilimumab, an anti-CTLA 4 immune checkpoint inhibitor, as an adjuvant therapy for patients with high risk stage III melanoma.

    Prof Eggermont describes the improved overall survival rate of five years, 11% high in the ipilumumab arm, as coming at the cost of immune related side effects associated with ipilimumab.

    • 5 min

Top Podcasts In Medicine

More by ecancer